Preclinical assessment of QLS-111, a novel ATP-sensitive potassium channel opener, alone and in combination with approved ocular hypotensive drugsPreclinical assessment of QLS-111, a novel ATP-sensitive potassium channel opener, alone and in combination with approved ocular hypotensive drugs